Acuta Capital Partners’s Relmada Therapeutics RLMD Stock Holding History

Acuta Capital Partners’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-365,618	Closed	-$13.5M	–	44
2022 Q3	$13.5M	Buy	365,618 +13,118	+4%	+$363K	5.83%	4
2022 Q2	$6.69M	Buy	352,500 +10,500	+3%	+$229K	3.73%	9
2022 Q1	$9.23M	Sell	342,000 -62,000	-15%	-$1.28M	4.31%	5
2021 Q4	$9.1M	Buy	+404,000	New	+$8.98M	3.83%	6
2021 Q1	–	Sell	-120,000	Closed	-$3.85M	–	57
2020 Q4	$3.85M	Sell	120,000 -157,000	-57%	-$5.39M	1.05%	34
2020 Q3	$10.4M	Buy	277,000 +42,500	+18%	+$1.64M	2.83%	12
2020 Q2	$10.5M	Buy	234,500 +143,550	+158%	+$6.07M	3.03%	10
2020 Q1	$3.1M	Buy	+90,950	New	+$3.67M	1.5%	24

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acuta Capital Partners's RLMD Position: Q4 2022 in Review

Acuta Capital Partners sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 365,618 shares — an estimated $13.5M sold.

Acuta Capital Partners first reported a position in RLMD in Q1 2020 and held it in 8 quarters. The position peaked at $13.5M in Q3 2022. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

Acuta Capital Partners reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
Acuta Capital Partners sold 365,618 Relmada Therapeutics shares in Q4 2022, an estimated $13.5M.
Acuta Capital Partners first reported a position in Relmada Therapeutics in Q1 2020 and held it in 8 quarters.
Acuta Capital Partners's Relmada Therapeutics position peaked at $13.5M in Q3 2022.
110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on Acuta Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.